Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

Low-molecular-weight heparin is the guideline-endorsed treatment for cancer-associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, limited data support its use in cancer patients.The primary outcome was major bleeding. Secondary outcomes included VTE recurrence and a composite of major plus clinically relevant non-major bleeding (CRNMB).Patients with cancer-associated VTE were randomly assigned to...